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a b s t r a c t 
Multiple SARS-CoV-2 vaccinations have shown excellent efficacy during clinical trials. However, post vaccine surveillance is important to confirm ‘real-world’ 
findings of vaccine efficacy and safety. It is therefore imperative to identify individuals that become infected with SARS-CoV-2 post vaccination. We investigated 
the vaccination status of staff that had tested positive in a cohort of healthcare workers in one large tertiary hospital in the UK. At the time of the investigation, 8 th 
December 2020 to 13 th March 2021, 11,871 staff had been vaccinated and 225 staff tested positive for SARS-CoV-2. This period coincided with the second wave of 
SARS-CoV-2 infections in the UK which was driven by the Alpha variant. No healthcare workers who were double vaccinated had a positive PCR test for SARS-CoV-2 




























































On the 8th December 2020 the world’s first dose of COVID-19 vac-
ine, was given to a recipient outside of clinical trials. This dose of Pfizer
ioNTec BNT162b2 was administered at University Hospital Coven-
ry and Warwickshire NHS Trust (UHCW), a large tertiary hospital lo-
ated in the West Midlands, England. Healthcare workers who receive
heir vaccine on the hospital site are only offered the Pfizer BioNTec
NT162b2. In rare circumstances where the Pfizer vaccination was con-
raindicated due to history of severe allergy, staff may have been vac-
inated elsewhere with the AstraZeneca (ChAdOx1). At the time of this
tudy these were the only two vaccines available in the UK. Clinical trial
ata for the Pfizer vaccination recommended an interval of 21 days be-
ween first and second doses of vaccine and vaccine induced protection
s considered to be achieved 14 days after the first vaccine dose. On the
0 th December 2020 the Joint Committee on Vaccination and Immuni-
ation (JCVI) decided to amend the vaccine schedule extent the interval
etween doses to 12 weeks, allowing more people to receive at least one
ose of vaccine to maximise the short term impact at a time when cases
f SARS-CoV-2 in the UK were high [1] . The subsequent speed at which
he vaccination programme in the UK has been rolled has been phe-
omenal. As of May 2021 36,704,672 first doses and 20,287,403 second
oses have been administered nationally [2] . Throughout the pandemic
t has been clear that front-line healthcare workers are at high risk of ac-
uiring SARS-CoV-2 infection and transmitting infection onto vulnera-
le groups of patients [3] . Due to this increased risk, healthcare workers
ere placed second on the JCVI prioritisation list [4] . Some healthcare
orkers who presented early for vaccine in the UK received 2 doses of
NT162b2 prior to the change in schedule. Post vaccine surveillance is r
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) mportant to confirm ‘real-world’ findings of vaccine efficacy and safety
emonstrated within clinical trial settings, especially when the recom-
ended regimen has been adapted. It is therefore imperative to identify
ndividuals that become infected with SARS-CoV-2 post vaccination to
etter understand protection offered by vaccination and the signs and
ymptoms of disease in this cohort. 
The SIREN study looked to understand impact of vaccination in
ealthcare workers in a group of staff who were undergoing regular
symptomatic screening for SARS-CoV-2 [5] . The roll-out of the vacci-
ation programme requires further investigation as to the impact on the
ncidence of COVID-19 in healthcare workers to extend on the work that
as been done by the SIREN study. Here we present the data from an au-
it of vaccination status of staff members at UHCW, who tested positive
or SARS-CoV-2 by PCR between 8 th December 2020 and 13 th March
021. This audit was carried out in the midst of the second wave in the
K which peaked in the last week of January 2021, the predominant
ariant in the UK at this time was Alpha (B.1.1.7). 
aterials and methods 
UHCW is a tertiary university hospital of 1250 beds covering a wide
ange of specialities. There are approximately 13,000 staff who work
cross the organisation. Positive SARS-CoV-2 PCR test results from staff
ested at UHCW were extracted from the laboratory information system
overing the period of the 8 th December 2020 to the 13 th March 2021.
taff that had positive SARS-CoV-2 PCR results from a nasopharyngeal
nd throat swab were cross-referenced with vaccination data to iden-
ify which of those staff who had tested positive during this period had
eceived at least one dose of vaccine. 021 
ticle under the CC BY-NC-ND license 
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o  Staff who tested positive > 14 days after their first dose of vaccina-
ion were contacted to participate in a survey relating to their positive
ARS-CoV-2 PCR result. The survey was conducted in April 2021 one
onth after the data collection period ended. Time from infection to
nswering the survey ranged from 1 -4 months, dependent on when
hey tested positive for SARS-CoV-2. The survey was delivered via tele-
hone or email and captured information on job role, ethnicity, reason
or seeking a SARS-CoV2 test, symptom timelines and any known con-
acts with a positive case of SARS-CoV-2. 
Under the Governance Arrangements for Research Ethics Commit-
ees (GAfREC), studies where staff are being approached due to the na-
ure of their role are exempt from requiring Research Ethics Committee
REC) approval. Therefore, local R&D approval was obtained via the
OVID-19 Research Committee to carry out this project within UHCW
HS Trust. 
esults and discussion 
Two hundred and twenty five staff that had tested positive for SARS-
oV-2 between the 8 th December 2020 and 14 th March 2021 were iden-
ified. Twelve staff were excluded due to inability to ascertain their vac-
ination status, reducing the cohort to 213 individuals ( Fig. 1 ). 
Of the 213 staff with a positive SARS-CoV-2 PCR test, 70 (33%) in-
ividuals had not received a single COVID-19 vaccination dose. Eighty
our (39%) individuals had received a single dose of vaccine after their2 ositive SARS-CoV-2 result. Therefore, no protection from vaccination
ould have been expected at the time they tested positive. 
Fifty-nine staff (28%) had received their first dose of vaccine be-
ween 2 to 69 days before they tested positive for SARS-CoV-2. Of the
9 staff who received their vaccine prior to testing positive for SARS-
oV-2; Thirty three of these individuals tested positive for SARS-CoV-2
ithin 10 days of vaccination and were therefore most likely incubating
he virus at the time of vaccination. Three staff tested positive at 10-14
ays after vaccine administration so possibly incubating at the time of
accination or shortly after having received the vaccine but would not
ave had sufficient time to mount a protective immune response. 
Twenty three staff members were vaccinated > 14 days before they
ested positive for SARS-CoV-2 (range 15-69 days), it therefore ap-
ears that their single dose of vaccine was not protective against infec-
ion. ( Fig. 1 ). All 23 health care workers had received Pfizer-BioNTech
NT162b2 vaccination. These 23 staff members were contacted and
sked to partake in a survey regarding their infection. Seventeen re-
ponses were received ( Table 1 ). 
Of these 23 staff members the majority were white British (76%). The
ost common reason for having a PCR test was due to ward outbreak
urveillance screening (8), followed by symptomatic screens (5), con-
rmation of positive asymptomatic lateral flow testing (3) and finally
ocial contact with a positive case (1). For these 23 staff the time from
accination to testing positive ranged from 15-69 days, with a median of
2.5 days. Three (17.6%) of the 17 staff members surveyed stated that
hey were asymptomatic at the time of testing and did not go onto de-
elop any symptoms attributable to SARS-CoV 2 at all after their positive
ARS-CoV-2 test. The remaining 14 staff members either had symptoms
t the time of the testing, or developed symptoms in the 3 days after
heir test. None of these staff required medical intervention or hospital-
sation. Ten staff members stated that they thought the transmission had
ccurred due to positive patient contact. Five staff members had contact
ith a positive household case. Two staff members had no known con-
act with individuals known to be infected with SARS-CoV-2. Surveys
ere conducted at the end of the study period, and therefore depending
pon when the infection took place, there may be an element of recall
ias when gathering information from study participants. 
Cycle threshold (CT) values in SARS-CoV-2 infected individuals can
ange from low to high and is dependent on multiple factors; including
he time the swab was taken in relation to the infectious period and the
wabbing technique. It can be used as a crude indication of the amount
f virus present in the oro/nasopharynx at the time of swabbing with a
ow CT value indicating a high level of viral RNA. CT values were re-
iewed from all positive SARS-CoV-2 PCR tests in this cohort and ranged
rom 16-35. Two individuals had swabs with CT values of < 20 and could
e considered to have a relatively high amount of viral RNA. Fifteen in-
ividuals had swabs with CT values ranging from 20-35 and could be
onsidered to have a relatively low amount of viral RNA. Inferring a
iral burden from CT values must be done with caution as a standard
urve was not used. However, the fact that the majority of these staff
embers had swabs with relatively low amounts of viral RNA is an ob-
ervation that requires further investigation to ascertain whether this is
 vaccine affect or not. This observation has been noted in other studies
hereby vaccinated individuals have a reduction in the amount of virus
etected by PCR [6] . 
It is of note that there was a significant number of staff (70; 32.9%)
ho had not at the time of the audit received a single dose of vaccine,
hen it had been available to them for approximately 3 months. While
t is recommended to wait a minimum of 4 weeks after a positive test
efore receiving the COVID-19 vaccine [7] , these staff tested positive
 4 weeks before their vaccination status was ascertained. Interestingly
he SIREN study also noted that vaccine coverage was significantly re-
uced in HCW’s who had had prior infection with SARS-CoV-2 [5] . It
ould be interesting to explore the reasoning of HCW’s reluctance to
resent for vaccination post-infection. Perhaps this is because of a fear























































Survey responses from staff members who tested positive for SARS-CoV-2 > 14 days after vaccination. 




















on day of test 
New or additional 






Medical 31 Yes White British Positive lateral flow 30 21 Siemens kPCR Coryza Migraine Anosmia Positive household contact 
Nursing 57 Yes White British COVID outbreak: 
surveillance screen 
20 20 Siemens kPCR Fatigue None Confirmed case on ward. 
Physiotherapist 27 Yes White British COVID outbreak: 
surveillance screen 
16 32 Siemens kPCR None None Confirmed case on ward. 
Portering 50 No White Irish Symptomatic 15 33 ∗ Abbott M2000 Cough Pyrexia None Positive household 
contact. 
Administration 19 No White British In contact with a 
person who was 
feeling unwell. 
17 17 ∗ Abbott M2000 None SOB Anosmia Ageusia Positive household and 
social contact 
Nursing 53 No White British Positive lateral flow 23 21 STARlet Seegene Fatigue SOB Headache 
Sweating 
None None 
Nursing 45 Yes White British Positive lateral flow 20 26 SRATlet Seegene Coryza Flu-like illness 
Myalgia 
SOB Anosmia Ageusia None 
Phlebotomist and health care 
assistant 
40 Yes Black African Symptomatic 24 33 STARlet Seegene ‘Itchy throat’ None Positive household 
contact. 
Mental health nursing 21 Yes White British COVID outbreak: 
surveillance screen 
22 34 Siemens kPCR None Chest pain SOB Confirmed case on ward. 
Specialist occupational 
therapist 
26 Yes White British COVID outbreak: 
surveillance screen 
18 34 Siemens kPCR None None Confirmed case on ward. 
Ward manager 33 Yes White British Symptomatic 53 30 STARlet Seegene Cough Fatigue ‘Severe’ 
headache 
None Confirmed case on ward. 
Health Care Assistant 57 Yes White British COVID outbreak: 
surveillance screen 
27 35 Siemens kPCR None Severe leg pains Confirmed case on ward. 
Physiotherapist 32 Yes White British COVID outbreak: 
surveillance screen 
31 24 STARlet Seegene Sore throat Cough Coryza Headache Confirmed case on ward. 
Trainee Advanced Nurse 
Practitioner 
37 Yes White British COVID outbreak: 
surveillance screen 
39 30 STARlet Seegene Coryza Headache Cough Confirmed case on ward. 
Health Care Assistant 49 Yes British Indian Symptomatic 64 28 Siemens kPCR Coryza Fever Cough 
Myalgia 
None Positive household 
contact. 
Nursing 52 Yes Indian Symptomatic 21 16 Siemens kPCR Fever Shivering Headache 
Productive cough 
None Confirmed case on ward. 
Activities Co-Ordinator 40 Yes White British COVID outbreak: 
surveillance screen 
69 29 STARlet Seegene None None Confirmed case on ward. 
SOB: shortness of breath 


















































































atural infection have more severe but still self-limiting flu-like symp-
oms post vaccination compared to SARS-CoV-2 naive counterparts [8] .
t may also be that staff who have been infected with SARS-CoV-2 are not
resenting for vaccination due to altruistic reasons; they have antibod-
es to SAR-CoV-2 and are therefore choosing to delay their vaccination
o someone else can go first. Data from SIREN interim analysis suggests
hat immunity from natural infection lasts at least 7 months in HCW’s
9] , therefore these individuals not being vaccinated at this stage of the
andemic is unlikely to have an impact on the national goal of reaching
 level of population immunity that will reduce the number of hospital-
sations associated with COVID-19. It must be noted that this is a cohort
ho are < 65 years of age and whether this duration of protection can be
xtrapolated to those > 65 or to those with underlying health conditions
s unclear. This hesitancy in health care workers who have had a previ-
us infection with SARS-CoV-2 to present for vaccination may need to
e considered when designing communication strategies around vacci-
ation and vaccine hesitancy in healthcare settings. 
As of the 13 th March 2021, 11,871 staff at UHCW had been vacci-
ated. Of those, 9488 had only one dose and 2383 staff had received
oth doses. Four hundred and fifty six staff received their first dose be-
ween the 28 th February and the 13 th March and would not have been
onsidered protected during this audit period. Therefore this gives us
n infection rate of 0.2% in our vaccinated cohort (23/11,415), and all
taff that became infected had only received one dose of vaccine (Pfizer
ioNTec BNT162b2). It should be noted we may be slightly under re-
orting the number of the infections in our staff cohort as some people
ay have chosen to be tested at an alternative testing centre which
ould be outside of the scope of this audit. The infection rate observed
n our cohort of staff is comparable to the findings of Keehner et al.
ho found an infection rate of 0.4% from 14 days after the first dose of
accine [10] . None of the staff members who completed the survey at
HCW had severe infection requiring hospital treatment. This is reassur-
ng and confirms data from studies that while not completely protective
gainst infection, there is significant protection from hospitalisation and
eath [11] . Reassuringly, none of the staff who tested positive during
he study period had two doses of vaccine. 
This is an evaluation looking at the vaccination status of our staff
hat tested positive for SARS-CoV-2 in the period from the 8th Decem-
er 2020 to the 13th March 2021. This study showed that a low num-
er of these infections (23 individuals) were from staff members who
ad been vaccinated in a time frame that would have been considered
rotective. This gives confidence that the vaccination programme is a
uccess. However, we cannot comment on the longevity of protection
ffered from vaccination and the coverage that will be offered against
ew variants that arise. Reassuringly, the staff members in this audit4 ere vaccinated while there were still very high rates of transmission
ccurring in the community, and we were in the midst of a second wave
ith Alpha (B.1.1.7) being the predominant strain. This wave peaked
n the last week of January 2021. So while this data offers real-world
vidence that the vaccine is effective in preventing infections in health
are workers, there is clearly need for further research into the impact
f vaccination on the amount of virus present in the oro/nasopharynx
nd its role in transmission and whether this changes between different
ARS-CoV-2 Variants. 
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